Breast Cancer Clinical Trial
The XENERAâ„¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Summary
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Eligibility Criteria
Inclusion Criteria:
Documented histologically confirmed breast cancer with ERand/ or PgR-positive and HER2-negative status
Locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy
Archival tumour sample available at the time of informed consent and provided to the central laboratory around the time of randomisation. Patients must provide a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample preferably taken at the time of presentation with recurrent or metastatic disease (provision of a biopsy sample taken from the bone is not acceptable).
Patients must satisfy the following criteria for prior therapy:
Disease progression during treatment or within 12 months of completion of endocrine adjuvant therapy or
Disease progression while on or within 1 month after the end of prior endocrine therapy for advanced/metastatic breast cancer (Note: the endocrine therapy does not have to be the treatment immediately prior to trial entry).
Patients must have
At least one measurable non-visceral lesion according to RECIST version 1.1 in either lymph nodes, soft tissue, skin and/or
At least one measurable non-visceral lesion according to RECIST version 1.1 as lytic or mixed (lytic + blastic) in bone and/or
At least one non-measurable (lytic, mixed lytic + blastic, or blastic) bone lesion according to RECIST version 1.1
Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
Fasting glucose <8.9 mmol/L (<160 mg/dL) and HbA1c <8.0%
Adequate organ function
Exclusion Criteria:
Previous treatment with agents targeting the IGF pathway, AKT, or mTOR pathways
Prior treatment with exemestane (except adjuvant exemestane stopped >12 months prior to start of study treatment as long as the patient did not recur during or within 12 months after the end of adjuvant exemestane)
Evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases, malignant pleural effusions, malignant peritoneal effusions) at screening. NOTE: Patients with a past history of visceral metastases are eligible if visceral metastases have completely resolved at least 3 months
History or evidence of metastatic disease to the brain
Leptomeningeal carcinomatosis
More than 1 prior line of chemotherapy for HR+ HER2- metastatic breast cancer
Radiotherapy within 4 weeks prior to the start of study treatment
Use of concomitant systemic sex hormone therapy
History or presence of cardiovascular abnormalities
Known pre-existing interstitial lung disease
Further exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 53 Locations for this study
Chandler Arizona, 85224, United States
Goodyear Arizona, 85338, United States
Beverly Hills California, 90211, United States
San Francisco California, 94158, United States
New Haven Connecticut, 06510, United States
Fort Myers Florida, 33901, United States
Athens Georgia, 30607, United States
Indianapolis Indiana, 46260, United States
Minneapolis Minnesota, 55455, United States
Kansas City Missouri, 64132, United States
Nyack New York, 10960, United States
Tulsa Oklahoma, 74133, United States
Nashville Tennessee, 37203, United States
Fort Worth Texas, 76104, United States
Salt Lake City Utah, 84106, United States
Tacoma Washington, 98405, United States
Tweed Heads New South Wales, 2485, Australia
Frankston Victoria, 3199, Australia
Bruxelles , 1200, Belgium
Jette , 1090, Belgium
Kortrijk , 8500, Belgium
Leuven , 3000, Belgium
Quebec , G1S 4, Canada
Avignon , 84000, France
Le Mans , 72000, France
Marseille , 13009, France
Paris , 75248, France
Paris , 75908, France
Pierre Benite , 69495, France
Toulouse , 31059, France
Erlangen , 91054, Germany
Karlsruhe , 76135, Germany
Athens , 11528, Greece
Heraklion , 71110, Greece
Larisa , 41334, Greece
Neo Faliro, Athens , 18547, Greece
Thessaloniki , 54645, Greece
Napoli , 80131, Italy
Padova , 35128, Italy
Roma , 00189, Italy
Lisboa , 1400-, Portugal
Loures , 2674-, Portugal
Vila Nova de Gaia , 4434-, Portugal
A Coruña , 15006, Spain
Barcelona , 08036, Spain
Lleida , 25198, Spain
Madrid , 28007, Spain
Madrid , 28034, Spain
Madrid , 28040, Spain
Málaga , 29010, Spain
Valencia , 46009, Spain
Valencia , 46010, Spain
Valencia , 46010, Spain
London , EC1A , United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.